GSK delivers further progress in Q2 and sets out new priorities for the Group
New Brunswick, N.J. (July 18, 2017) – Johnson & Johnson (NYSE: JNJ) today announced sales of $18.8 billion for the second quarter of 2017, an increase of 1.9% as compared to the second quarter of 2016. Operational sales results increased 2.9% and the negative impact of currency was 1.0%. Domestic sales increased 1.6%. International sales increased 2.3%, reflecting operational growth of 4.4% and a negative currency impact of 2.1%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 0.5%, domestic sales decreased 1.0% and international sales increased 2.0%.*
The Medical Research Council (MRC) and UCB have launched a new scheme designed to help accelerate work on the development of antibody-based therapeutics.
US-based molecular diagnostics firm Asuragen has launched the QuantideX qPCR BCR-ABL minor Kit designed to monitor molecular response in patients with chronic myeloid leukaemia (CML).
Researchers at the University of Bristol in the UK have developed a new technology to aid general practitioners in prescribing antibiotics and to assist in fighting antibiotic resistance.
Accelerating access to pancreatic surgery has been shown to boost success rates by more than a fifth with a cost saving to the NHS of around £3,200 per patient.
Growth in prescriptions for diabetes medicines is exceeding the rise in overall prescribing, according to new figures from NHS Digital.
A research team at the University of California, Riverside (UC Riverside) in the US has evaluated a new device manufactured by tissue sampling devices maker Histologics.
US-based Sciex Diagnostics has launched a new fully integrated LC-MS solution, Sciex Topaz System, for use in clinical diagnostics.
US-based life sciences firm Emergent BioSolutions has secured around $23m for the development of a new multi-drug auto-injector to deliver nerve agent antidote.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.